Zimbabwe’s Medicines Authority orders recall of Azithromycin over quality concerns

ZIMBABWE—Zimbabwe’s Medicines Control Authority (MCAZ) has ordered a recall of a widely distributed batch of Azithromycin following failed quality tests.

The antibiotic, manufactured by Indoco Remedies Limited in India, failed dissolution testing during a routine 24-month stability study.

Details of the recall

The recall specifically affects Azithromycin 500 mg USP Tablets, Batch Number 24050191.

MCAZ announced the Class II recall on Monday, extending the directive to the retail level across the country.

The manufacturer voluntarily reported the quality issue after discovering out-of-specification results during the stability assessment.

Healthcare facilities nationwide have received orders to immediately isolate and quarantine all affected stock.

Licensed wholesalers, pharmacies, public and private clinics, and hospitals must cooperate with both Indoco Remedies Limited and local distributors to complete the recall process.

Health implications and risks

The identified quality defect raises significant public health concerns.

When dissolution testing fails, medications may not break down properly in the body, potentially preventing patients from receiving therapeutic doses.

This inadequacy could compromise the antibiotic’s effectiveness in treating bacterial infections and contribute to antimicrobial resistance if patients do not achieve sufficient drug levels in their bloodstream.

Those who bought this batch are urged to return it to the pharmacy.

Patients who recently took the affected medication should consult their healthcare professionals for guidance and reassessment of their condition.

MCAZ emphasized that healthcare providers, licensed pharmaceutical stakeholders, and the general public should take these precautions seriously.

The authority will continue monitoring the recall process and release updates as necessary.

The recall points out the importance of quality assurance in pharmaceutical manufacturing.

Zimbabwe’s regulatory body has demonstrated its commitment to protecting public health by acting swiftly on the manufacturer’s voluntary report.

This action ensures that substandard medicines do not remain in circulation where they could harm patients or fuel the dangerous rise of drug-resistant infections.

Indoco Remedies Limited has initiated the recall process in cooperation with local distribution networks across Zimbabwe.

Citizens have also been encouraged to verify their antibiotic stocks and take action if they possess the recalled batch.